Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2017 | What can biosimilars offer us?

Richard Markus • 26 Sep 2017
ESMO 2017
General ABP 980 Trastuzumab

Biosimilars, molecules intended to mimic the structure and function of existing pharmaceutical agents, are still in the early stages of being implemented into cancer treatments. Richard Markus, MD, PhD, from Amgen, Los Angeles, CA discusses the intended purpose of biosimilars and talks about why Amgen feel that their new biosimilar of trastuzumab, ABP 980, is an important new addition to the field. This interview was recorded at the European Society for Medical Oncology (ESMO) 2017 conference held in Madrid, Spain.

More from Richard Markus

How were biosimilars discussed at ESMO 2017?
1:01
How were biosimilars discussed at ESMO 2017?
Richard Markus • 26 Sep 2017
Critical data points in the production of biosimilars
1:05
Critical data points in the production of biosimilars
Richard Markus • 26 Sep 2017
The potential of biosimilars in cancer treatment
0:32
The potential of biosimilars in cancer treatment
Richard Markus • 26 Sep 2017

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals